CorriXR Therapeutics was given the “Most Promising New Company” award by attendees at the inaugural Delaware’s DNA 2023 Life Science Conference.
Sponsored by Delaware Bio, the conference attracted 300 people to network and hear panels about industry trends.
CorriXR, the first spin-out of ChristianaCare’s Gene Editing Institute, is an oncology-focused biotherapeutics development company with what they describe as a ground-breaking gene editing platform technology.
The startup was competing with four others for the title by presenting a three-minute pitch about what they were doing and how they were doing it to the conference audience, who voted for the winner.
Also in the running were:
- Cosmos Pharmaceuticals – The medical device company focuses on the relationship between medication adherence and patient outcomes.
- Hartlon – The start-up is developing a resorbable vascular stent designed to salvage limbs that are at risk of amputation by restoring blood flow below the knee.
- BioCurie – BioCurie is developing an AI software platform that will revolutionize cell and gene therapy (CGT) production to make these lifesaving therapies faster, better and cheaper.
- Cellergy Pharma – Cellergy Pharma develops novel immunotherapies for the treatment of severe allergic diseases.
- Innovative Precision Health – Innovative Precision Health (IPH) is a healthcare technology company that provides comprehensive solutions for precision health. Its platform integrates data collection, analysis and interpretation and is implemented nationwide.
- Nitro Biosciences – Nitro Biosciences is a startup from the University of Delaware developing a live bacterial vaccine platform to target diseases/antigens normally hidden from the immune system.
As top vote getter, CorriXR will receive a $2,500 prize and runners-up Cosmos and Hartlon each will receive $1,000.
“We congratulate CorriXR, Cosmos and Hartlon on this exciting achievement and recognition, and thank all our participating companies for helping make our first-ever conference a huge success,” said Michael Fleming, president of Delaware Bio. “Small life science companies are the largest, and fastest-growing segment of our membership and the pitch competition demonstrated the strength and diversity of our startup ecosystem.”
RELATED STORY: 300 pack Delaware DNA life sciences conference
Dr. Eric Kmiec, CorriXR and CEO thanks Delaware Bio for the chance to strengthen relationships in the state.
“We are grateful for the continued support as a start-up company developing novel gene editing therapies for cancer,” he said.
Cosmos founder Alexander Colton said it was a privilege to present about his company.
“Delaware’s tightly connected entrepreneurial hub is a critical part of Cosmos’s success and we are excited to launch our product FortisKap later this year from my home state,” Colton said.
Jack Scanlon of Hartlon said he appreciated the opportunity to interact with leaders in the Delaware life science ecosystem.
“We are so pleased by this recognition,” he said. “It makes clear that people understand both the severity of the health problem Hartlon is addressing and the transformational potential of our breakthrough drug delivery technology.”
Held on May 11, Delaware’s DNA: 2023 Life Science Conference, convened global, regional and state bioscience sector leaders for a full-day program exploring the industry’s most critical issues and opportunities.
Betsy Price is a Wilmington freelance writer who has 40 years of experience.
Share this Post